BridgeMD
New treatment option for Post Partum Hemorrhage
Official title Oxytocin Pharmacokinetics and Pharmacodynamics
ClinicalTrials.gov ID: NCT05488457
What this study is testing
What is deuterated oxytocin (d5OT)?
deuterated oxytocin (d5OT) is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for post partum hemorrhage.
Also referred to as Deuterium-labeled oxytocin.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50, women only
You may be able to join if
- 18-50 years old
- intrauterine pregnancy
- term (\>39 weeks gestation or 37-39 weeks gestation with fetal or maternal medical indication for delivery) pregnancy
- non-emergent (scheduled or unscheduled) cesarean delivery
You likely can't join if
- allergy or contraindication to oxytocin
- inability to provide informed consent
The study team makes the final eligibility decision.
Where it's taking place
- Stanford, California, United States
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 50 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Stanford, California, United States; Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.